JTE-013

SKU: orb1308169

Description

JTE-013

Research Area

Cell Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 383150-41-2
• MW: 408.29
• Purity: 99.65%
• Formula: C₁₇H₁₉Cl₂N₇O
• SMILES: CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12
• Target: LPL Receptor,Apoptosis,S1P Receptor
• Solubility: 10% DMSO+40% PEG300+5% Tween-80+45% Saline:3.3 mg/mL (8.08 mM);DMSO:250 mg/mL (612.31 mM)

Bioactivity

• Target IC50:
  S1P2 (human):17 nM|S1P2 (rat):22 nM
• In Vivo:
  JTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) decreases tumor size and tumor weight. the modification of JTE-013 to produce the AB1 compound improved potency, intravenous pharmacokinetics, cellular activity, and antitumor activity in NB and may have enhanced clinical and experimental applicability.
• In Vitro:
  JTE-013 is a S1P2 antagonist. JTE-013 (50-200 μM; 1-3 days) decreased cell viability. JTE-013 shows 4.2% inhibition of S1P3 and does not antagonize S1P1 at concentrations up to 10 μM. JTE-013 (10-1000 nM; 30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, Lysophospholipid Receptor, LPLReceptor, LPL, LPL Receptor, inhibit, JTE 013, JTE013, JTE-013, Apoptosis, S1P2, S1P2 for human, S1P2 for rat, S1P Receptor, S1PReceptor

Compound Identifiers

PubChem CID

10223146